OSSIO Inc
OSSIO is an orthopedic fixation company committed to transforming the orthopedic experience for patients, physicians and payors. Founded in 2014, its vision is to provide the first credible replacement to metal implants in the multibillion-dollar global orthopedic fixation market with its OSSIOfiber Intelligent Bone Regeneration Technology. OSSIO’s development headquarters is located in Caesarea, Israel, and its commercial headquarters is in Woburn, Mass. (USA).
Company details
Find locations served, office locations
- Business Type:
- Technology
- Industry Type:
- Clinical Services
- Market Focus:
- Globally (various continents)
- Year Founded:
- 2014
Who We Are
Our Mission:
OSSIO® strives to become THE gold standard in orthopedic fixation by encouraging natural bone healing that will ultimately eliminate hardware removal procedures, minimize implant-related complications, alleviate pain, and dramatically improve the healthcare economics of orthopedics.
We are committed to transforming the orthopedic experience for patients, physicians, and payors. Our vision is to provide the first credible replacement to metal implants in the $15B+ orthopedic fixation market (screws, pins, plates) with Intelligent Bone Regeneration Technology.
OSSIOfiber® represents a breakthrough material platform for orthopedic and podiatric surgeons who seek a more biologically friendly way to restore patient stability and mobility with nothing permanent left behind.
Our Story
Founded in 2014, OSSIO began as the culmination of years of biomechanical research and a vision for the possibility of better bone healing. The technological basis of OSSIOfiber was developed and would lay the groundwork for ushering in a new breakthrough category of non-permanent fixation: “Bio-Integrative” implants that have been both the desired strength AND bio-friendliness. Implants that have the mechanical strength for easy insertion and secure fixation, while enabling the body to regrow bone, incorporating and replacing the implant (without the adverse inflammation and weakness often seen in “bio-resorbables” and other “bio-composites”), has remained elusive to the industry — until now.
OSSIO® has its commercial headquarters in Boston, Massachusetts and development headquarters in Caesarea, Israel. We are a young, fast-growing company that is always on the lookout for talented people to join our multidisciplinary team.